sec filing
MD
NASDAQ · MDGL
Madrigal Pharmaceuticals, Inc.
Healthcare · Biotechnology
$523.26
Down-$16.80 (-3.11%)
Updated Sep 16, 2026, 10:56 AM
SID Score
5.6/10
Composite research score
Smart Money
62/100
Neutral
- Market cap
- 12.67B
- P/E ratio
- -45
- Dividend yield
- 0.00%
- 52-week range
- $393.61 – $615.00
- Volume
- 259.41K
- Avg. volume
- 340.65K
Price performance
MDGL price history
1M range · 20 trading sessions · Daily adjusted prices
MDGL closed at $523.26 after 20 trading sessions, down 0.21% for the selected period.
- Last close
- $523.26
- Period change
- -0.21%
- Period low
- $511.97
- Period high
- $546.93
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $539.25 | $539.71 | $513.36 | $523.26 | 259.41K |
| Sep 14, 2026 | $540.00 | $541.345 | $527.97 | $540.06 | 156.54K |
| Sep 11, 2026 | $536.02 | $546.56 | $531.365 | $534.49 | 187.64K |
| Sep 10, 2026 | $543.12 | $543.12 | $519.095 | $533.12 | 225.77K |
| Sep 9, 2026 | $529.50 | $549.97 | $526.88 | $546.66 | 281.26K |
| Sep 8, 2026 | $534.17 | $540.00 | $526.67 | $534.16 | 199.46K |
| Sep 4, 2026 | $536.82 | $547.92 | $535.60 | $541.08 | 177.17K |
| Sep 3, 2026 | $548.83 | $552.08 | $540.44 | $542.61 | 143.46K |
| Sep 2, 2026 | $543.54 | $551.45 | $537.095 | $546.93 | 202.82K |
| Sep 1, 2026 | $540.03 | $548.60 | $532.655 | $538.71 | 165.75K |
| Aug 31, 2026 | $530.60 | $542.05 | $523.29 | $540.03 | 134.58K |
| Aug 28, 2026 | $539.38 | $542.16 | $528.285 | $533.76 | 268.66K |
| Aug 27, 2026 | $538.46 | $545.815 | $532.30 | $543.69 | 221.85K |
| Aug 26, 2026 | $510.14 | $550.33 | $507.48 | $538.88 | 345.54K |
| Aug 25, 2026 | $515.95 | $523.35 | $506.29 | $512.16 | 189.2K |
| Aug 24, 2026 | $515.89 | $517.00 | $507.175 | $511.97 | 145.52K |
| Aug 21, 2026 | $520.09 | $530.67 | $514.905 | $516.74 | 179.83K |
| Aug 20, 2026 | $537.01 | $539.73 | $518.65 | $519.09 | 264.48K |
| Aug 19, 2026 | $528.99 | $542.775 | $527.46 | $540.16 | 221.13K |
| Aug 18, 2026 | $524.50 | $533.68 | $514.57 | $524.37 | 356.2K |
Latest MDGL news
The latest Smart Investors Daily articles mentioning MDGL.
Stock researchCompany · Overview
MDGL research
Overview
Company profile and research snapshot.
Company profile
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $595.40
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 4, 2026 | Wolfe Research | Outperform | — |
| Aug 3, 2026 | Barclays | Overweight | — |
| Jul 29, 2026 | Canaccord Genuity | Buy | — |
| Jul 27, 2026 | Wells Fargo | Overweight | — |
| Jun 11, 2026 | B of A Securities | Neutral | — |
News briefing
Data unavailable
Market data is busy. Please try again shortly.
AI research layers
Interpretive context generated from the platform’s current data sources.
Data unavailable
Market data is busy. Please try again shortly.